In a trial with patients with recurrent or advanced prostate cancer, it has been found that in some of them pembrolizumab, an immune therapy drug, has a spectecular success. In order to minimize side effects it is now important to find out whether there is a method to predict for whom the drug is helpful.
Contact: info(@)neat-news(dot)com.
neat-news.com is not responsible for the content of external sites.
We do not link to external sites in return for money or any other benefits.
Note that photos are usually stock photos, mostly taken from
Wikipedia, which we can use royalty-free either since they are in
the public domain or available under an open licence such as
a share alike licence.
The page is maintained in Germany and for any legal matters the
laws of Germany apply.
Any warranty or liability is excluded in the widest legally
possible sense.
© neat-news.com 2016-2025.
